Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit. The drugmaker also hiked its forecast for 2024 well beyond analyst expectations after sales of Mounjaro more than tripled in the year’s first quarter. Lilly said it was still dealing with supply issues, with strong demand for both drugs outpacing its production hikes. But the company expects its most significant increases to occur in... Read this story
